see ya at $45
Cormark upgrades BlackBerry to Top Pick, says performance “remarkable”
April 1, 2013 By Cantech
Cormark analyst Richard Tse said the long weekend provided him a little extra time to review BlackBerry’s Q4and fiscal 2013 results, which were released last Thursday.
Tse says he came away from the extended review with more confidence in the Canadian smartphone maker, and has upgraded the stock to “Top Pick” rating. The Cormark analyst has a $20 one-year target price on BlackBerry.
Tse says BlackBerry’s Q4, in which it reported operating EPS of $0.22 on revenue of $2.7-billion, provided continued evidence that the company’s new management team is more than up to the task of successfully transitioning BlackBerry to its new platform.
“In our view, given the hyper competitive market and major internal product transition, we believe the results of the past two quarters have been nothing short of remarkable,” said Tse. “Operating improvements thus farunder such extreme challenges give us reason to believe in BlackBerry’s ability to execute on BB10 as having better odds than we originally would ha
Hearing Unconfirmed Takeover Chatter in Amarin | Benzinga
Free Streaming News ... Hearing Unconfirmed Takeover Chatter in Amarin. Charles Gross, Benzinga Staff Writer. March 28, 2013
(Extreme Revalant To Earnings )
ARTICLE: BlackBerry Short Seller Squeeze Watch
By: George Kesarios
CEO Thorsten Heins has some good news ahead of the report. In an interview just two days ago in the Australian Financial Review, he said:
In the context of the financial viability of the company that is where I shake my head sometimes and wonder what everyone is talking about. The company has no debt, I will report pretty good cash position by the end of March in my earnings call, so I think we did a really diligent job in, not just keeping the company afloat, but also bringing it back to health.
So we have a given that the company will report a good cash position. This is very important because it tells us that the company will not have a problem building up inventory.
I don't know what short sellers are thinking, but they better adjust their thesis as to why they have shortedthis stock to begin with, because things might get out of hand and they might be "running for cover" very soon. L
do the dd
my god if your trading know the rules.
Seeking Alpha By: Briam Wilson 3/26/13
Pimavanserin is an inverse agonist of the serotonin receptor 5-HT2A. Molecules working through the same mechanism of action have had limited success so far, which is why pimavanserin in a particularly attractive molecule right now that may pique the interest of other pharmaceutical companies interested in expansion of their psychotic drug pipelines.
This, combined with Acadia's (still) low market capitalization of ~$660 million (at the time of writing) makes Acadia a prime acquisition target for big pharmaceutical companies, particular those that are struggling with their top-line growth.